Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
metabolism | lysosome | | |
inhibition of caspase-4 activity protects PPT1 cells from undergoing apoptosis and from abnormal intracellular accumulation of fatty-acylated proteins and peptides leading to PPT1 pathogenesis
| metabolism | lysosome | | |
a source of recombinant PPT1 will also be useful for exploring alternative delivery methods, such as injection into brain ventricles, chemical modifications or chronic high-dose therapy | metabolism | lysosome | | |
Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis |
| | | |